Janus Henderson Group PLC Buys 10,270 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Janus Henderson Group PLC increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 22.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 56,288 shares of the medical research company's stock after acquiring an additional 10,270 shares during the period. Janus Henderson Group PLC owned about 0.11% of Charles River Laboratories International worth $10,390,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Pinnacle Bancorp Inc. boosted its stake in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. Optiver Holding B.V. bought a new position in Charles River Laboratories International in the 4th quarter valued at approximately $37,000. GeoWealth Management LLC boosted its position in Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after buying an additional 190 shares during the period. Pilgrim Partners Asia Pte Ltd bought a new stake in Charles River Laboratories International during the 4th quarter worth approximately $48,000. Finally, Tortoise Investment Management LLC increased its position in Charles River Laboratories International by 77.7% in the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after acquiring an additional 115 shares during the period. Institutional investors own 98.91% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. cut their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target on the stock in a research report on Wednesday, May 14th. Morgan Stanley lowered their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 5th. Robert W. Baird lifted their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. Finally, Barclays increased their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $172.31.

Charles River Laboratories International Stock Down 0.6%

Shares of NYSE CRL traded down $0.85 during trading on Thursday, hitting $134.13. 74,719 shares of the company traded hands, compared to its average volume of 1,509,782. The firm has a market capitalization of $6.59 billion, a price-to-earnings ratio of 893.90, a P/E/G ratio of 4.54 and a beta of 1.50. The business's fifty day moving average is $133.64 and its 200 day moving average is $164.14. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. During the same period in the prior year, the business earned $2.27 EPS. The firm's revenue for the quarter was down 2.7% on a year-over-year basis. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares of the company's stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.30% of the stock is owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).